Revvity (RVTY) Set to Post Quarterly Earnings on Tuesday

Revvity (NYSE:RVTY) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Revvity to announce earnings of $1.30 per share and revenue of $694.73 million for the quarter. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. On average, analysts expect Revvity to post $5.36 EPS for the current fiscal year and $5.92 EPS for the next fiscal year.

Revvity Trading Down 5.3%

Shares of Revvity stock opened at $156.95 on Monday. Revvity has a 1 year low of $81.22 and a 1 year high of $169.06. The company has a market cap of $17.51 billion, a price-to-earnings ratio of 74.74, a PEG ratio of 2.86 and a beta of 1.08. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The company’s fifty day simple moving average is $144.54 and its 200-day simple moving average is $112.15.

Wall Street Analyst Weigh In

A number of research analysts recently commented on RVTY shares. Royal Bank Of Canada began coverage on Revvity in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price target for the company. TD Cowen increased their price target on Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Evercore reaffirmed an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. UBS Group started coverage on Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price target on the stock. Finally, KeyCorp raised their price target on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Five equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $124.43.

Insider Activity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. The trade was a 52.49% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 9,045 shares of company stock valued at $1,281,439. 0.85% of the stock is currently owned by corporate insiders.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.